<PAGE> 1
Exhibit 99.4
July 28, 2000
Board of Directors
King Pharmaceuticals, Inc.
501 Fifth Street
Bristol, Tennessee 37620
Members of the Board:
We hereby consent to the inclusion of our opinion letter to the Board of
Directors of King Pharmaceuticals, Inc. ("King") as Annex B to the Joint Proxy
Statement/Prospectus of King and Jones Pharma Incorporated ("Jones") as filed
with the SEC on July 28, 2000 relating to the proposed merger transaction
involving King and Jones and references thereto in such Joint Proxy
Statement/Prospectus under the caption "Opinions of Financial Advisors--Opinion
of King's Financial Advisor." In giving such consent, we do not admit that we
come within the category of persons whose consent is required under, and we do
not admit that we are "experts" for purposes of, the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder.
CREDIT SUISSE FIRST BOSTON CORPORATION
/s/ Paul S. Henderson
--------------------------------------
By: Paul S. Henderson
Its: Director
